Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Gilead Sciences

Status and phase: Terminated; Phase 2

Conditions: Small Lymphocytic Lymphoma; Follicular Lymphoma

Treatments: Drug: Idelalisib; Biological: Rituximab

Study type: Interventional

Funder types: Industry

Identifiers

NCT02258529

GS-US-313-1414

Details and patient eligibility

About

The primary objective of this study is to evaluate the overall response rate (ORR) and complete response (CR) rate to treatment with idelalisib in combination with rituximab in previously untreated adults with follicular lymphoma (FL) or small lymphocytic lymphoma (SLL).

An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated those studies in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA). All front-line studies of idelalisib, including this study, were also terminated.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Histologically confirmed diagnosis of B-cell lymphoma
• No previous systemic treatment for lymphoma
• Subject demonstrates need for treatment for lymphoma
• Ann-Arbor Stage 2 (noncontiguous), 3, or 4 disease
• Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy
• Adequate performance status
• Required baseline laboratory data within protocol-specified parameters

Key Exclusion Criteria:

• Known history of transformed lymphoma or diffuse large cell lymphoid malignancy
• Known history of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma
• Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
• Known history of drug-induced liver injury, chronic active hepatitis B (HBV), chronic active hepatitis C (HCV), alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis
• Ongoing inflammatory bowel disease
• Known human immunodeficiency virus (HIV) infection
• History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
• Ongoing immunosuppressive therapy, including systemic corticosteroids (> 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for autoimmune anemia and/or thrombocytopenia

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Idelalisib + rituximab

Experimental group

Description:

Idelalisib + rituximab for up to 104 weeks

Treatment:

Biological: Rituximab

Drug: Idelalisib